2-Propoxy-Adenosine | 50257-83-5

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2-Propoxy-Adenosine
• 英文别名: 2-n-Propoxy-adenosin；(2R,3R,4S,5R)-2-(6-amino-2-propoxypurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 50257-83-5
• 化学式: C₁₃H₁₉N₅O₅
• 分子量: 325.324
• InChiKey: BOHZYKDFAJFENY-WOUKDFQISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  149
• 氢给体数：
  4
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2-氯腺嘌呤核苷 在 sodium hydroxide 作用下， 以 丙醇 、 乙醇 为溶剂， 生成 2-Propoxy-Adenosine
  参考文献：
  名称：

  ADP and ATP analogues, process for making and administration to inhibit

  摘要：

  公式I的化合物已被披露，其中Q代表CR.sup.1 R.sup.2，R代表O或CR.sup.3 R.sup.4，W代表O或CH.sub.2，R.sup.1，R.sup.2，R.sup.3和R.sup.4分别代表氢或卤素，X代表S(O).sub.n R.sup.5，烷基C.sub.1-6，烷氧基C.sub.1-6，酰胺基C.sub.1-6，CONR.sup.6 R.sup.7，NR.sup.8 R.sup.9，卤素，含有5-或6-成员的含硫杂环，或苯基，可选地由烷基C.sub.1-6取代，n代表0、1或2，R.sup.5代表芳基或烷基C.sub.1-6，可选地由一个或多个亲水基、烷氧基C.sub.1-6、卤素和芳基取代的基团取代；R.sup.6，R.sup.7，R.sup.8和R.sup.9独立地代表氢或烷基C.sub.1-6，Y代表NH.sub.2或烷氧基C.sub.1-6，Z代表酸性基团，此外，当R代表CR.sup.3 R.sup.4时，--Q--Z也可以代表羟基或--OP(O)(OH).sub.2，及其药学上可接受的盐，具有某些限制条件，用作药物。

  公开号：

  US05654285A1

文献信息

• Therapeutic Compounds
  申请人：Pritchard Martyn

  公开号：US20080221060A1

  公开（公告）日：2008-09-11

  Use of compounds of general formula (A) as medicaments is described, in particular for the treatment of pain or inflammation; wherein: (I) when X=OH, R 2 =NH 2 , R 5 =CH 2 OH, R 6 =H, R 1 is C 5 -C 6 alkoxy, OCH 2 Cyclopropyl, O-(2,2,3,3-tetrafluoro-cycloButyl), phenoxy, substituted phenoxy, OCH 2 CH 2 OH, or OCH 2 CHF 2 , (5-indanyl)oxy, C 1 , C 2 , C 5 , or C 6 alkylamino, (R) or (S)-sec-Butylamino, C 5 or C 6 cycloalkylamino, exo-norbornane amino, (N-methyl, N-isoamylamino), phenylamino, phenylamino with either methoxy or fluoro substituents, a C 2 sulfone group, a C 2 alkyl group, a cyano group, a CONH 2 group, or 3,5-dimethylphenyl; or when X=H, R 2 =NH 2 , R 5 =CH 2 OH, R 6 =H, R 1 is n-hexyloxy; or (II) when X=OH, R 1 =H, R 5 =CH 2 OH, R 6 =H, R 2 is NMe 2 , N-(2-isopentenyl), piperazinyl, (N-Me, N-benzyl), (N-Me, N—CH 2 Ph(3-Br)), (N-Me, N—CH 2 Ph(3-CF 3 )), or (N-Me, N-(2-methoxyethyl)), or OCH 2 Cyclopentyl; or (III) when X=OH, R 5 =CONHR 3 , R 6 =H: R 1 is H, R 3 is an isopropyl group, and R 2 is either NH 2 or a methylamino group (NHMe) or an isoamyl group (CH 2 CH 2 CHMe 2 ); or R 1 is H, R 3 is H, and R 2 is NH 2 ; or R 1 is OMe, R 3 is Ph, and R 2 is NH 2 ; or R 1 is NHCH 2 CH 2 CH 2 CH 2 CH 2 Me, R 3 is CH 2 CH 2 CH 2 Me, and R 2 is NH 2 ; or (IV) when X=OH, R 1 =H, R 2 =NH 2 , R 5 =CH 2 NHCOR 4 , R 6 =H, R 1 is n-propyl or NHCH 2 CH 3 ; or (V) when X=OH, R 5 =CH 2 OH, R 6 =H: R 1 is NHCyclohexyl when R 2 is NMe 2 ; or R 1 is OMe when R 2 is NHBenzyl; or (VI) when X=OH, R 2 =NH 2 , R 5 =CH 2 OH, R 6 =Me, R1 is NHCyclohexyl or NHCyclopentyl.

  描述了一般式（A）化合物的药物应用，特别是用于治疗疼痛或炎症；其中：（I）当X = OH，R2 = NH2，R5 = CH2OH，R6 = H，R1为C5-C6烷氧基，OCH2环丙基，O-（2,2,3,3-四氟-环丁基），苯氧基，取代苯氧基，OCH2CH2OH或OCH2CHF2，（5-吲哚基）氧基，C1，C2，C5或C6烷基氨基，（R）或（S）-sec-丁基氨基，C5或C6环烷基氨基，外-去环辛烷氨基，（N-甲基，N-异戊基氨基），苯基氨基，带有甲氧基或氟代取代基的苯基氨基，C2磺酰基，C2烷基，氰基，CONH2基或3,5-二甲基苯基；或当X = H，R2 = NH2，R5 = CH2OH，R6 = H，R1为正己氧基；或（II）当X = OH，R1 = H，R5 = CH2OH，R6 = H，R2为NMe2，N-（2-异戊烯基），哌嗪基，（N-Me，N-苄基），（N-Me，N-CH2Ph（3-Br）），（N-Me，N-CH2Ph（3-CF3））或（N-Me，N-（2-甲氧基乙基）），或OCH2环戊基；或（III）当X = OH，R5 = CONHR3，R6 = H：R1为H，R3为异丙基基团，R2为NH2或甲基氨基（NHMe）或异戊基基团（CH2CH2CHMe2）；或R1为H，R3为H，R2为NH2；或R1为OMe，R3为Ph，R2为NH2；或R1为NHCH2CH2CH2CH2CH2Me，R3为CH2CH2CH2Me，R2为NH2；或（IV）当X = OH，R1 = H，R2 = NH2，R5 = CH2NHCOR4，R6 = H，R1为正丙基或NHCH2CH3；或（V）当X = OH，R5 = CH2OH，R6 = H：当R2为NMe2时，R1为NHCyclohexyl；或当R2为NHBenzyl时，R1为OMe；或（VI）当X = OH，R2 = NH2，R5 = CH2OH，R6 = Me，R1为NHCyclohexyl或NHCyclopentyl。
• ATP analogues
  申请人：Astra Pharmaceuticals Limited

  公开号：EP0508687A1

  公开（公告）日：1992-10-14

  There are disclosed compounds of formula I,    wherein Q represents CR1R2,    R represents O or CR3R4,    W represents O or CH2,    R1, R2, R3 and R4 independently represent hydrogen or halogen,    X represents S(O)nR5, alkyl C₁₋₆, alkoxy C₁₋₆, acylamino C₁₋₆, CONR6R7, NR8R9, halogen, a 5- or 6-membered S containing heterocycle, or phenyl optionally substituted by alkyl C₁₋₆,    n represents 0, 1 or 2,    R5 represents aryl or alkyl C₁₋₆ optionally substituted by one or more substituents selected from hydroxy, alkoxy C₁₋₆, halogen and aryl;    R6, R27, R8 and R9 independently represent hydrogen or alkyl C₁₋₆,    Y represents NH2 or alkoxy C₁₋₆, and    Z represents an acidic moiety,    in addition, when R represents CR3R4, then -Q-Z may also represent hydroxy or -OP(O)(OH)2,    and pharmaceutically acceptable salts thereof, with certain provisos, for use as pharmaceuticals.

  公开了式 I 的化合物、 其中 Q 代表 CR1R2、 R 代表 O 或 CR3R4、 W 代表 O 或 CH2、 R1、R2、R3 和 R4 独立地代表氢或卤素、 X 代表 S(O)nR5、烷基 C₁₋₆、烷氧基 C₁₋₆、酰氨基 C₁₋₆、CONR6R7、NR8R9、卤素、含杂环的 5 或 6 元 S 或任选被烷基 C₁₋₆ 取代的苯基、 n 代表 0、1 或 2、 R5 代表芳基或 C₁₋₆烷基，任选被选自羟基、C₁₋₆烷氧基、卤素和芳基的一个或多个取代基取代； R6、R27、R8 和 R9 独立地代表氢或 C₁₋₆ 烷基、 Y 代表 NH2 或 C₁₋₆ 烷氧基，以及 Z 代表酸性分子、 此外，当 R 代表 CR3R4 时，-Q-Z 也可以代表羟基或-OP(O)(OH)2、 及其药学上可接受的盐，但有某些限制条件，可用作药物。
• 2-Alkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor
  作者：Masayuki Ueeda、Robert D. Thompson、Luis H. Arroyo、Ray A. Olsson

  DOI：10.1021/jm00108a014

  日期：1991.4

  A Langendorff guinea pig heart preparation served for the assay of agonist activity of a series of 24 2-alkoxyadenosines at the A1 and A2 adenosine receptors of, respectively, the atrioventricular node (conduction block) and coronary arteries (vasodilation). Activities are low at the A1 receptor and do not show a clear relationship to the size or hydrophobicity of the C-2 substituent. All the analogues are more potent at the A2 receptor, activity varying directly with the size and hydrophobicity of the alkyl group. The most potent analogue in this series, 2-(2-cyclohexylethoxy)adenosine, has an EC50 of 1 nM for coronary vasodilation and is 8700-fold selective for the A2 receptor.
• UEEDA, MASAYUKI;THOMPSON, ROBERT D.;ARROYO, LUIS H.;OLSSON, RAY A., J. MED. CHEM., 34,(1991) N, C. 1334-1339
  作者：UEEDA, MASAYUKI、THOMPSON, ROBERT D.、ARROYO, LUIS H.、OLSSON, RAY A.

  DOI：——

  日期：——
• ATP ANALOGUES
  申请人：FISONS plc

  公开号：EP0579643A1

  公开（公告）日：1994-01-26